Elezanumab ELISA Kit (DV303018)

Fiche technique Partager le produit Copier les informations

Aperçu
Images
Reférences
Fiche technique
SDS

Aperçu

Numéro de catalogue	DV303018
Description	Elezanumab ELISA Kit (DV303018) — Quantitative sandwich ELISA for Elezanumab. Sample: Plasma, Serum. Range: 0.31-5 μg/mL. Sensitivity: 0.156 μg/ml. Highlights ●Sandwich Format — High specificity, reliable quantification. ●High Sensitivity — Optimized for low-abundance target detection. ●Ready-to-Use — Complete kit with pre-coated plates included.
Type d'échantillon	Plasma, Serum
Sensibilité	0.156 μg/ml
Plage	0.31-5 μg/mL
Numéro d'accès	Q96B86
Applications	ELISA
Méthode de détection	Colorimetric
Type de test	Quantitative
Retraitement	80-120%
Expédition	2-8 ℃
Stabilité et stockage	The stability of ELISA kit is determined by the loss rate of activity. The loss rate of this kit is less than 10% prior to the expiration date under appropriate storage condition.
Spécifications	Elezanumab
Noms alternatifs	ABT-555, AE12-1Y-QL (derived from parental mAb AE12-1 and AE12-1Y), 1791416-49-3
Contexte	Repulsive guidance molecule A (Elezanumab) is a ~49 kDa protein. Member of the repulsive guidance molecule (RGM) family that performs several functions in the developing and adult nervous system. Regulates cephalic neural tube closure, inhibits neurite outgrowth and cortical neuron branching, and the formation of mature synapses. Binding to its receptor NEO1/neogenin induces activation of RHOA-ROCK1/Rho-kinase signaling pathway through UNC5B-ARHGEF12/LARG-PTK2/FAK1 cascade, leading to collapse of the neuronal growth cone and neurite outgrowth inhibition. Furthermore, RGMA binding to NEO1/neogenin leads to HRAS inactivation by influencing HRAS-PTK2/FAK1-AKT1 pathway. It also functions as a bone morphogenetic protein (BMP) coreceptor that may signal through SMAD1, SMAD5, and SMAD8.
Note	For Research Use Only.